PLS-123

LPS-123 is a covalently irreversible BTK inhibitor with an IC50 of AKT/mTOR and MAPK signaling pathways, activation of PLCγ2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research[1].

Product Specifications

CAS Number

[1431727-04-6]

UNSPSC

12352005

Target

Akt; Apoptosis; Btk; CCR; ERK; mTOR; p38 MAPK

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=C(NC1=CN=C(NC2=CC=CC(NC(CNC(C=C)=O)=O)=C2)N=C1)C3=CC(NC(C4=CC=CC(C(F)(F)F)=C4)=O)=CC=C3C

Molecular Formula

C31H26F3N7O4

Molecular Weight

617.58

References & Citations

[1]Ding N, et al. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget. 2015 Jun 20;6 (17) :15122-36.